Endocrine therapy (ET) use in the pre-operative setting in localized estrogen receptor (ER)-positive breast cancer (BC) is associated with comparable rates of response and breast preservation relative to chemotherapy but lower toxicity in post-menopausal women1. The gene discussed is ESR1; the disease is breast cancer.